Department of Epidemiology and Population Health, Stanford University School of Medicine, Stanford, CA, 94306, USA.
Department of Pediatrics, McGovern Medical School, University of Texas Health Science Center, Houston, TX, 77030, USA.
J Perinatol. 2022 Oct;42(10):1301-1305. doi: 10.1038/s41372-022-01381-x. Epub 2022 Mar 31.
To investigate whether hospital rates of active treatment for infants born at 22-23 weeks is associated with survival of infants born at 24-27 weeks.
We included all liveborn infants 22-27 weeks of gestation delivered at California Perinatal Quality Care Collaborative hospitals from 2015 to 2019. We assessed (1) the correlation of active treatment (e.g., endotracheal intubation, epinephrine) in 22-23 week infants and survival until discharge for 24-27 week infants and (2) the association of active treatment with survival using multilevel models.
The 22-23 week active treatment rate was associated with infant outcomes at 22-23 weeks but not 24-27 weeks. A 10% increase in active treatment did not relate to 24-25 week (adjusted OR: 1.00 [95% CI: 0.95-1.05]), or 26-27 week survival (aOR: 1.02 [0.95-1.09]).
The hospital rate of active treatment for infants born at 22-23 weeks was not associated with improved survival for 24-27 week infants.
研究 22-23 周出生婴儿的积极治疗率是否与 24-27 周出生婴儿的存活率相关。
我们纳入了 2015 年至 2019 年在加利福尼亚围产期质量协作医院出生的所有 22-27 周的活产婴儿。我们评估了（1）22-23 周婴儿的积极治疗（例如气管内插管、肾上腺素）与 24-27 周婴儿的出院存活率之间的相关性，以及（2）使用多层次模型评估积极治疗与存活率之间的关系。
22-23 周的积极治疗率与 22-23 周婴儿的婴儿结局相关，但与 24-27 周婴儿的结局无关。积极治疗增加 10%与 24-25 周（调整后的 OR：1.00[95%CI：0.95-1.05]）或 26-27 周的存活率（aOR：1.02[0.95-1.09]）无关。
22-23 周出生婴儿的医院积极治疗率与 24-27 周出生婴儿的存活率提高无关。
